Arcutis Biotherapeutics, Inc. (ARQT) financial statements and ratios from SEC XBRL: revenue $0.5B (TTM), net margin -4.3%, revenue growth 91.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $376.07M |
| Revenue (TTM) | $0.5B |
| Net Margin | -4.3% |
| Operating Margin (TTM) | 9.9% |
| Net Debt / EBITDA | -6.5 |
| Revenue Growth (YoY) | 91.3% |
| EPS Growth (YoY) | -88.8% |
| FCF Growth (YoY) | -94.4% |
| EV / EBITDA | 476.3 |
| Price / Book | 14.30 |
| Price / Sales | 7.17 |
| FCF Yield | -0.4% |
| Altman Z-Score | 5.54 (safe) |
| Piotroski F-Score | 4/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ARQT overview · ARQT earnings · ARQT KPIs · ARQT documents · ARQT ownership · ARQT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.